Van Berkom & Associates Inc. Has $86.45 Million Holdings in Charles River Laboratories International, Inc. $CRL

Van Berkom & Associates Inc. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 501,152 shares of the medical research company’s stock after acquiring an additional 50,462 shares during the quarter. Charles River Laboratories International comprises 2.9% of Van Berkom & Associates Inc.’s holdings, making the stock its 7th largest holding. Van Berkom & Associates Inc.’s holdings in Charles River Laboratories International were worth $86,449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. Jones Financial Companies Lllp lifted its position in shares of Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the period. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International during the first quarter worth $418,000. American Century Companies Inc. increased its position in shares of Charles River Laboratories International by 41.9% during the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after buying an additional 1,616 shares during the period. Brown Advisory Inc. raised its stake in Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after buying an additional 114 shares during the last quarter. Finally, California Public Employees Retirement System lifted its holdings in Charles River Laboratories International by 3.9% in the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after buying an additional 3,198 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director James C. Foster sold 75,000 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating in a research report on Monday. Morgan Stanley lifted their price objective on Charles River Laboratories International from $220.00 to $260.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Robert W. Baird set a $213.00 price objective on Charles River Laboratories International in a research note on Friday, May 8th. Mizuho upped their target price on Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Finally, Evercore reaffirmed an “outperform” rating and set a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $220.75.

Charles River Laboratories International Stock Down 0.1%

Charles River Laboratories International stock opened at $224.19 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $237.86. The firm’s fifty day moving average is $192.74 and its 200 day moving average is $186.65. The company has a market capitalization of $10.80 billion, a PE ratio of -59.63, a PEG ratio of 2.50 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. Charles River Laboratories International’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.